Illustrated Research Methods to Determine the MOA of Cytolin
It was April of 2009 when Search For A Cure originally composed our first due diligence report for Dr. Eric Rosenberg after seeking out advisement from experts in the field to determine if we should offer our support for the experimentation and development of a particular antibody that targets LFA-1, known as Cytolin. It was based on that report that Dr. Rosenberg agreed to undertake a series of experiments with his post doctoral student Jenna Reychert endeavoring to identify the mechanism of action of the antibody.
Since this initial effort, we have dedicated ourselves to fulfilling a mission of seeing the avenue of monoclonal antibodies for therapies and for prevention seriously explored in all possible forms. The team at Mass General Hospital have completed their first round of research and have uncovered some promising and interesting facts about the anti-LFA-1 Mab, Cytolin, which has been published in the Virology Journal. Here you will find a graphic depiction of the article that they published, which may help you to follow and understand the process used for identifying the MOA of the antibody. We are composing an evaluation of the landscape of antibodies in development now in anticipation of a second national antibodies for HIV meeting, and will have more content soon to hopefully put this research in a better context.
Pictorial Journey in S. Africa - '99
Some of the images and memories wonderful and difficult to relive from our journeys in South Africa. We learned so much in Africa that it is difficult to put into words, so we will leave the pictures to speak for themselves.
Pictorial Journey in Malawi - '99
Some of the images and memories wonderful and difficult to relive from our journeys in Malawi. We have not given up on Malawi as well and hope to return to see our old friends there soon. Hopefully bearing good news! We miss and cherish you.
Pictorial Journey in India - '99
Some of the images and memories wonderful and difficult to relive from our journeys in India. We have not given up on India and hope to return to see our old friends there soon. Hopefully bearing good news!
ATAC's DDC Committee Meeting on Therapeutic Antibodies
On February 1, 2013 in San Diego, CA Search For A Cure hosted a committee meeting of some of the best and brightest HIV/AIDS activists who have been engaged at the highest levels of patient advocacy and therapeutic development strategy since the early days of the epidemic.
The group, known as the AIDS Treatment Activists Coalition (ATAC), is a national coalition of AIDS activists – many living with HIV/AIDS – working together to end the AIDS epidemic by advancing research on HIV. We brought them together with representation from CytoDyn Inc., the company responsible for the continued development of the monoclonal antibody PRO140, to discuss the entire field of monoclonal antibodies and their role in the future as tools for combating HIV/AIDS.
World AIDS Day 2012 - Thank You John Auerbach
Presentation of The Search For A Cure PULSE Award
Presented With Thanks to Commissioner of Public Health John Auerbach
World AIDS Day Celebration, Massachusetts State House, Boston, MA
Held on December 5th, 2012
Published in Fresh Foods For Thought
Wednesday, 28 November 2012 10:10
A History and Future of Antibodies for HIV
Through a long and often misunderstood use antibodies have been instramental agents for the achievement of health, resistance, and immunization. From the imbibment of toxins to garner resistance to their poisons by Mithridates the Sixth, to the discovery and classification of antibodies as the "Magic Bullet" by Paul Ehrlich in the early 1900's, to the now over 30 patented FDA approved monoclonal antibodies as therapeutic agents by the modern medical industry for centuries we have been leveraging this naturally binding agent for its high specificity to targets, gentle metabolization by the body, and long half-life.
This is the story of the history of antibodies, their use and the discovery of how to manipulate and design them for specific purposes, and their potential future and role as important therapeutic agents to ease the burden of treatment for HIV patients and to help in bringing about the end of transmission and the end of the HIV epidemic.
Friday, 19 October 2012 10:57
PRO140: A Game Changer for People with HIV
Yesterday there was the announcement of the official acquisition of the monoclonal antibody PRO-140 from Progenics Pharmaceuticals by CytoDyn Inc. As the monoclonals continue to emerge as useful tools for other areas of medicine, we are pleased to share the value that they represent to the HIV community. We feel it is especially important to pursue research in this area as the data shared with us on our Jan. 13th roundtable discussion with experts in the field physicians demonstrates that these therapies really can work. Please read more to begin to understand why these long lasting therapeutics are so important to our community.
Friday, 21 September 2012 15:44
IAVI Efforts to Coordinate bNAbs
The International AIDS Vaccine Initiative (IAVI) is a global not-for-profit organization whose mission is to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world. Founded in 1996, IAVI works with partners in 25 countries to research, design and develop AIDS vaccine candidates.
Here you will find a video summary of their work on bNAbs as a method to derive an AIDS Vaccine.